Frequently Asked Questions

EMDrugs is an educational pharmacology platform for healthcare professionals and trainees involved in emergency care.

  • Content is based on independent reviews of current medical literature and the clinical experience of emergency physicians.

  • Scientific and pharmacological information is written and edited by specialist emergency physicians, in collaboration with other healthcare professionals.

EMDrugs is intended for educational and informational purposes only and does not constitute medical advice.

How did EMDrugs originate, and who writes its content?

EMDrugs was founded in Santiago, Chile, in 2021 by Dr. CristĆ³bal SĆ”a. He is an Emergency Medicine specialist who leads the platform as Editor-in-Chief and serves as its principal author.

  • Since 2023, Dr. JoaquĆ­n Chuecas, an emergency physician and clinical toxicologist, has contributed to the development and review of its content, alongside other physicians and medical specialists.

  • Content is based on current medical literature and supported by more than 1,500 scientific references.

Emergency Medicine community debut

EMDrugs has been available online since 2021. In 2024, after reaching a solid base of pharmacological content, the platform was presented at the inaugural FLAME Congress in Buenos Aires, Argentina.

  • This marked the beginning of broader outreach, with EMDrugs growing to hundreds of users internationally.

We specialize in emergency medicine pharmacology, presenting medications in a practical and concise manner.

Our core content includes:

  • Drug descriptions
  • Comparative tables of related medications

These are organized by pharmacological class or clinical application, focusing on medications most relevant to emergency care. Content is continuously expanding and regularly updated.

Examples include:

  • Induction agents and neuromuscular blocking agents
  • Fibrinolytic therapy
  • Vasopressors and inodilators
  • Bronchodilators
  • Anticonvulsants
  • Biological products and immunization
  • Toxicology, decontamination, and antidotes

Yes. EMDrugs focuses on pharmacology from the perspective of Emergency Medicine.

Our content is structured to provide:

  • Concise executive summaries
  • Relevant pharmacological information organized by specific scenarios

We emphasize the evidence supporting different medication uses, distinguishing between well-established indications and those with limited or uncertain evidence.

Limitations: We focus on medications commonly used in emergency care and do not aim to be exhaustive. EMDrugs complements other resources such as drug interaction checkers, pregnancy and lactation databases, and comprehensive drug databases.

EMDrugs is officially available in English and Spanish.

  • Translations between both languages are manually reviewed and edited to maintain linguistic and clinical consistency.

EMDrugs provides open-access Executive Summaries for medications.

Full membership access includes:
  • Full drug monographs
  • Comparative tables
  • Scientific references
  • Customizable settings
  • Personal notes and favorites

Membership plans:

  • Physician: US$48/year
  • Healthcare Professional (non-physician): US$36/year
  • Trainee: US$24/year

All plans include full access to EMDrugs.

You can install EMDrugs as a web app directly from your browserā€”no App Store required.

How?

  1. Open EMDrugs in your preferred browser (Chrome or Safari)
  2. Tap the red INSTALL button in the menu and follow the instructions.

Notes:

  • Works like a native app for quick and convenient access.
  • Add it to your home screen just like any other app.
  • Available on Android and iPhone (works best on Chrome and Safari).